104 related articles for article (PubMed ID: 17091545)
1. [The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Bouma M; Rutten GE; Wiersma T
Ned Tijdschr Geneeskd; 2006 Oct; 150(42):2339-40. PubMed ID: 17091545
[No Abstract] [Full Text] [Related]
2. [The 'Diabetes mellitus type 2' guideline (first revision) of the Dutch College of General Practitioners: response from family practice].
van den Bosch WJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(33):1685-6. PubMed ID: 10494307
[TBL] [Abstract][Full Text] [Related]
3. [The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Bouma M; Rutten GE; Wiersma T
Ned Tijdschr Geneeskd; 2006 Oct; 150(42):2339. PubMed ID: 17089555
[No Abstract] [Full Text] [Related]
4. [Summary of the practice guideline 'Diabetes mellitus type 2' (first revision) of the Dutch College of General Practitioners].
Wiersma TJ; Heine RJ; Rutten GE
Ned Tijdschr Geneeskd; 1999 Aug; 143(33):1688-91. PubMed ID: 10494309
[TBL] [Abstract][Full Text] [Related]
5. [The practice guideline 'Diabetes mellitus type 2' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice].
Rikken B
Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2233-4. PubMed ID: 17076355
[TBL] [Abstract][Full Text] [Related]
6. Metformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes management.
Halimi S
Diabetes Metab; 2006 Dec; 32(6):555-6. PubMed ID: 17296508
[No Abstract] [Full Text] [Related]
7. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of intensive glucose control in type 2 diabetes.
Mühlhauser I
N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
[No Abstract] [Full Text] [Related]
9. Self-monitoring of blood glucose: a test for patients or health-care professionals?
Bhatnagar D
Ann Clin Biochem; 2009 Jul; 46(Pt 4):271-2. PubMed ID: 19654101
[No Abstract] [Full Text] [Related]
10. Diabetes in the new General Medical Services contract: targets and adherence to metformin therapy.
Kirby M
Int J Clin Pract; 2005 Mar; 59(3):263-6. PubMed ID: 15857318
[No Abstract] [Full Text] [Related]
11. [The 'Diabetes mellitus type 2' guideline (first revision) of the Dutch College of General Practitioners: response from internal medicine].
Erkelens DW
Ned Tijdschr Geneeskd; 1999 Aug; 143(33):1686-8. PubMed ID: 10494308
[TBL] [Abstract][Full Text] [Related]
12. Implications of the United Kingdom Prospective Diabetes Study.
American Diabetes Association
Diabetes Care; 2000 Jan; 23 Suppl 1():S27-31. PubMed ID: 12017673
[No Abstract] [Full Text] [Related]
13. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
14. Self-monitoring of blood glucose in diabetes: is it worth it?
O'Kane MJ; Pickup J
Ann Clin Biochem; 2009 Jul; 46(Pt 4):273-82. PubMed ID: 19454538
[TBL] [Abstract][Full Text] [Related]
15. Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice.
Almirall J; Bricullé M; Gonzalez-Clemente JM
Nephrol Dial Transplant; 2008 Jul; 23(7):2436-8. PubMed ID: 18388117
[No Abstract] [Full Text] [Related]
16. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic treatment of type 2 diabetes mellitus: realities and perspectives.
Abdallah MP; Hirbli K
J Med Liban; 1999; 47(4):233-7. PubMed ID: 10641451
[No Abstract] [Full Text] [Related]
18. [Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective].
Pinto D; Heleno B; Gallego R; Santos I; Santiago LM; Maria V
Acta Med Port; 2011; 24(2):331-8. PubMed ID: 22011607
[TBL] [Abstract][Full Text] [Related]
19. [Type 2 diabetes: explosive issues in routine care].
Aumiller J
MMW Fortschr Med; 2009 Oct; 151(42):20. PubMed ID: 19938775
[No Abstract] [Full Text] [Related]
20. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
